Brian I Rini MD FASCO

Genitourinary Oncology, Hematologic Oncology

Brian Rini, MD, FASCO Professor of Medicine Chief of Clinical Trials Vanderbilt-Ingram Cancer Center

3601 21st Ave SNashville, TN 37232
Phone+1 615-936-2000

Dr. Rini is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rini's full profile Already have an account?

Summary

Dr. Brian Rini is an oncology specialist located in Nashville, TN at Vanderbilt University Medical Center, with subspecialties in genitourinary and hematologic oncology. He completed his fellowship in Hematology and Medical Oncology at the University of Chicago after finishing his residency and medical degree at the same institution, and he holds a BA from the University of Notre Dame. From 2005-2020, he was on staff at the Cleveland Clinic Health System, having served previously as an Assistant Professor at the University of California San Francisco School of Medicine. Dr. Rini's expertise spans GU Oncology especially renal cell carcinoma. His recent publications include works on renal cell carcinoma in leading medical journals, and he has contributed to multiple clinical trials focusing on treatments for metastatic renal cell carcinoma. He has received several honors, including CMS Meaningful Use Certifications and recognition as a Regional Top Doctor and Outstanding Mentor.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1998 - 2001
University of ChicagoResidency, Internal Medicine, 1995 - 1998
Ohio State University College of MedicineClass of 1995
University of Notre DameBA, 1987 - 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2001 - Present
TN State Medical License 2019 - 2027
OH State Medical License 2005 - 2021
AL State Medical License 2020 - 2020
IL State Medical License 1995 - 2002
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2014, 2016-2017

Clinical Trials

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
COMPLETED
PHASE2
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
UNKNOWN
PHASE2
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
COMPLETED
PHASE3

Publications & Presentations

PubMed

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Toni K Choueiri, Jaime Merchán, Amita Patnaik, Alexandra Drakaki, Brian I Rini
Nature. 2026-08-01
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Toni K Choueiri, Jaime Merchán, Amita Patnaik, Alexandra Drakaki, Brian I Rini
Nature. 2026-08-01
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.
Brian I Rini, Benjamin Garmezy
Oncology and Therapy. 2026-06-26

Journal Articles

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
The Association Between Facility Case Volume and Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era
Timothy Gilligan, Jorge A Garcia, Brian I Rini, Urologic Oncology
Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal Therapy
Vadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate

Books/Book Chapters

Textbook of Uncommon Cancer.
Chapter: Uncommon Tumors of the Kidney
Khaled Ali, Ming Zhou, Steve Campbell, Ronald M. Bukowski and Brian I. RiniEditors: Derek Raghavan, Charles D. Blanke, David H. Johnson, Paul L. Moots, Gregory H. Reaman, Peter G. Rose.John Wiley & Sons, IncEdition 4,
Renal Cell Carcinoma: Clinical Management.
Campbell SC, Rini BISpringer Science, Human Press, New York, NY
Cancer Management: A Multi-disciplinary Approach.
Chapter: Urothelial and kidney cancers
Rini BI, Hurwitz MEdition 11,

Abstracts/Posters

An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy.
Elizabeth R. Plimack, Cheryl Nemec, Paul Elson, Cristina Suarez, Tanya B Dorff, James M. G. Larkin, Cecilia McAleer, Isaac Nunez, Rosalie Anne Fisher, and Brian I. Rini, Asco Meeting Abstract
Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients.
M. Dror Michaelson, Brian I. Rini, Bernard J. Escudier, Joseph Clark, Bruce Redman, Jamal Christo Tarazi, Brad Rosbrook, Sinil Kim, and Robert John Motzer, Asco Meeting Abstracts May 30, 2012:4546
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Data...
Wanling Xie, Toni K. Choueiri, Jae-Lyun Lee, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Takes..., Asco Meeting Abstracts May 30, 2012:4538

Lectures

Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion...
2019 ASCO Annual Meeting - 6/1/2019
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediat...
2019 ASCO Annual Meeting - 6/1/2019
Cell Carcinoma: Bridging the Gap between Evidence and Clinical Practice.
Canton, Ohio

Other

Kidney cancer: Does hypothyroidism predict clinical outcome?
Rini B, Nat Rev Urol. 2011 Jan;8(1):10-1. PMID: 21116300
Editorial comment.
Rini BI, Shah SN, Urology. 2010 May;75(5):1114-5
Editorial Comment.
Campbell SC, Rini BI, J Urol. 182(6):2599-600

Press Mentions

FDA’s Oncologic Drugs Advisory Committee Splits Vote on Breast and Prostate Cancer DrugsMay 1st, 2026
A New Standard? Merck's Welireg Combos Deliver 1-2 Punch to Kidney CancerFebruary 28th, 2026
People with Cancer Benefit from COVID BoostersAugust 21st, 2025